Advertisement
Singapore markets close in 3 hours 30 minutes

  • Straits Times Index

    3,257.59
    +32.42 (+1.01%)
     

  • Nikkei

    37,560.27
    +121.66 (+0.32%)
     

  • Hang Seng

    16,761.82
    +250.13 (+1.52%)
     

  • FTSE 100

    8,023.87
    +128.02 (+1.62%)
     

  • Bitcoin USD

    66,379.95
    +369.43 (+0.56%)
     

  • CMC Crypto 200

    1,397.66
    -8.33 (-0.59%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • Dow

    38,239.98
    +253.58 (+0.67%)
     

  • Nasdaq

    15,451.31
    +169.30 (+1.11%)
     

  • Gold

    2,327.50
    -18.90 (-0.81%)
     

  • Crude Oil

    83.02
    +0.17 (+0.21%)
     

  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     

  • FTSE Bursa Malaysia

    1,564.61
    +5.02 (+0.32%)
     

  • Jakarta Composite Index

    7,120.97
    +47.15 (+0.67%)
     

  • PSE Index

    6,502.30
    +58.22 (+0.90%)
     

Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021

Altimmune, Inc.
·1-min read

GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the first quarter 2021 financial results and provide a business update.

Conference Call Information:

Date:

Monday, May 17, 2021

Time:

8:30 am Eastern Time

Domestic Dial-in:

877-423-9813

International Dial-in:

201-689-8573

Conference ID:

13719206

Webcast:

http://public.viavid.com/index.php?id=144634

About Altimmune

ADVERTISEMENT

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor & Media Contacts:

Will Brown

Stacey Jurchison

Chief Financial Officer

Sr. Dir, Investor Relations

Phone: 240-654-1450

Phone : 410-474-8200

wbrown@altimmune.com

sjurchison@altimmune.com